PRESCRIPTION DRUG IMPORT-ACT
HB3134 creates the Canadian Prescription Drug Importation Act and directs the Illinois Department of Public Health to establish a program to import certain prescription drugs from Canada when doing so is expected to produce cost savings for the State. The bill is aimed at drugs that are safe, effective, and eligible under federal law, and it requires the Department to contract with one or more vendors to manage the program, develop and update a wholesale importation list, identify compliant Canadian suppliers, and oversee distribution and reporting.
The program is limited by a series of safety, compliance, and eligibility requirements. Imported drugs must meet federal standards, cannot violate patent law, and exclude certain categories such as controlled substances, biological products, and some injectable or infused drugs. The bill also requires supply-chain documentation, testing by qualified laboratories, surety bonding or comparable security, annual audits, quarterly reports, and immediate suspension authority if violations or safety concerns arise. The Department must seek federal approval before implementation and may not spend implementation funds beyond the approval request until that approval is received.
If enacted, HB3134 would create a new state program and new administrative duties for the Department of Public Health, including rulemaking, vendor contracting, supplier vetting, reporting, and oversight of imported prescription drugs. It would also establish a framework for limited importation into Illinois for certain state-related purchasers and participants, including Medicaid pharmacies, the Department of Corrections, commercial plans approved by the federal government, and licensed pharmacists or wholesalers approved by the Department. The bill would interact with federal prescription drug importation law, the federal Food, Drug, and Cosmetic Act, and the Drug Supply Chain Security Act, while also affecting procurement rules by temporarily exempting vendor selection from the Illinois Procurement Code for three years.
The bill’s stated purpose and structure suggest a generally favorable policy approach toward lowering prescription drug costs while preserving safety controls. The findings section emphasizes high U.S. drug prices and the potential for savings through Canadian importation, indicating strong support for the concept of importation as a cost-reduction strategy. No committee transcripts or recorded votes were provided, so there is no direct evidence of legislative debate, amendments, or formal opposition in the available record.
The main points of contention are likely to be the balance between lower drug costs and concerns about drug safety, supply-chain integrity, and federal preemption. The bill itself acknowledges risks involving source verification, quality, purity, and patent compliance, and it responds with extensive testing, documentation, and suspension provisions. Potentially contentious issues also include the scope of eligible drugs and importers, the temporary exemption from the Illinois Procurement Code for vendor selection, and whether the program can be implemented without conflicting with federal approval requirements or patent law. No specific opposing lawmakers or stakeholder positions are identified in the provided materials.